| Ms Mary Sibert Fox, MD | |
|
3200 Canyon Lake Dr, Rapid City, SD 57702-8114 | |
| (605) 355-2423 | |
| (605) 355-2403 |
| Full Name | Ms Mary Sibert Fox |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 3200 Canyon Lake Dr, Rapid City, South Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306800784 | NPI | - | NPPES |
| 5549050 | Medicaid | SD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 3829 (South Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Mary Sibert Fox, MD 3200 Canyon Lake Dr, Rapid City, SD 57702-8114 Ph: (605) 355-2423 | Ms Mary Sibert Fox, MD 3200 Canyon Lake Dr, Rapid City, SD 57702-8114 Ph: (605) 355-2423 |
News Archive
Vaughn McCall, M.D., M.S., professor and chairman of the Department of Psychiatry and Behavioral Medicine, told a special consensus panel at the National Institutes of Health (NIH) that he could find no evidence that randomized controlled clinical trials had ever been conducted for five of the 10 pharmaceuticals prescribed most often for chronic insomnia.
Too often, it's only after a transplanted organ has sustained serious damage that a biopsy reveals the organ is in rejection. A new screening method using sensor particles and a urine test could catch rejection much earlier, more comprehensively, and without a biopsy needle.
In its quest to find new strategies to treat osteoarthritis and other diseases, a Boston University-led research team has reported finding a new computer tomography contrast agent for visualizing the special distributions of glycosaminoglycans (GAGs) - the anionic sugars that account for the strength of joint cartilage.
Centric Health Corporation, Canada's leading diversified healthcare services company, today announced financial results for the second quarter ended June 30, 2011.
Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
› Verified 3 days ago
Kimberly Hushagen, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 2905 5th St, Rapid City, SD 57701 Phone: 605-341-7337 | |
Sam L Mortimer, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2905 5th St, Rapid City, SD 57701 Phone: 605-341-7337 Fax: 605-341-2447 | |
Stephen M Kovarik, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2905 5th St, Rapid City, SD 57701 Phone: 605-341-7337 Fax: 605-341-2447 | |
Rachel C Edelen, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 640 Flormann St, Rapid City, SD 57701 Phone: 605-718-3300 Fax: 605-718-3426 | |
Gregory Anderson, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 2905 5th St, Rapid City, SD 57701 Phone: 605-341-7337 Fax: 605-341-2447 | |
Dr. Alicia Palmer Hooten, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2905 5th St, Rapid City, SD 57701 Phone: 605-341-7337 |